Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00024024 · ClinicalTrials.gov registry record · Phase 1
BMS-275291 in Treating Patients With HIV-Related Kaposi's Sarcoma
A Phase 1 study, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 1
- Development phase
- 59
- Enrollment target
NCT00024024: Completed Phase 1 study, sponsored by National Cancer Institute (NCI).
NCT00024024 is a Phase 1 study that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 59 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00024024, a Phase 1 study, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 59 participants
- Enrollment target
Study Summary
Phase I/II trial to study the effectiveness of BMS-275291 in treating patients who have HIV-related Kaposi's sarcoma. Drugs such as BMS-275291 may stop the growth of Kaposi's sarcoma by stopping blood flow to the tumor.
Interventions
- DRUG rebimastat
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 59 participants |
| Start Date | 2001-08 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00024024
The ClinicalTrials.gov registry entry for NCT00024024 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 59 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which rebimastat is the first listed.
NCT00024024 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00024024 about?
NCT00024024 is a clinical study titled "BMS-275291 in Treating Patients With HIV-Related Kaposi's Sarcoma". Phase I/II trial to study the effectiveness of BMS-275291 in treating patients who have HIV-related Kaposi's sarcoma. Drugs such as BMS-275291 may stop the growth of Kaposi's sarcoma by stopping blood flow to the tumor.
What is the current status of trial NCT00024024?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 59 participants. The study started on 2001-08.
What interventions are being tested in trial NCT00024024?
The interventions under investigation include: rebimastat (DRUG).
Who is sponsoring clinical trial NCT00024024?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.